gms | German Medical Science

83. Jahresversammlung der Deutschen Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie e. V.

Deutsche Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie e. V.

16.05. - 20.05.2012, Mainz

FDG Tracer-Uptake In Locally Advanced Oropharyngeal Squamous Cell Carcinoma

Meeting Abstract

  • corresponding author presenting/speaker Shachi J Sharma - Department of Otorhinolaryngology, Head and Neck Surgery. University of Giessen/Germany, Giessen, Germany
  • author Steffen Wagner - Department of Otorhinolaryngology, Head and Neck Surgery. University of Giessen/Germany, Giessen, Germany
  • author Dagmar Steiner - Department of Nuclear Medicine. University of Giessen/Germany, Giessen, Germany
  • author Claus Wittekindt - Department of Otorhinolaryngology, Head and Neck Surgery. University of Giessen/Germany, Giessen, Germany
  • author Detlef Litzlbauer - Department of Nuclear Medicine. University of Giessen/Germany, Giessen, Germany
  • author Jens P Klussmann - Department of Otorhinolaryngology, Head and Neck Surgery. University of Giessen/Germany, Giessen, Germany

German Society of Oto-Rhino-Laryngology, Head and Neck Surgery. 83rd Annual Meeting of the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery. Mainz, 16.-20.05.2012. Düsseldorf: German Medical Science GMS Publishing House; 2012. Doc12hno24

doi: 10.3205/12hno24, urn:nbn:de:0183-12hno246

Veröffentlicht: 23. Juli 2012

© 2012 Sharma et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Introduction: HPV-associated oropharyngeal squamous cell carcinoma (OSCC) is an own tumor entity with increasing incidence and different metastatic behavior compared to the non-HPV-associated OSCC. PET/CT has been described as a predictive marker for outcome of irradiation therapy in non-HPV-associated OSCC but its prognostic value for the HPV-associated OSCC is currently unknown.

Methods: 18-F FDG-PET/CT was conducted in 20 patients with locally advanced OSCC before panendoscopy. HPV-status was obtained via PCR and p16-immunohistochemistry. SUV-values of the primary tumor and corresponding metastases in both tumor entities were analysed.

Results: 6 out of 20 patients (30%) showed HPV-associated OSCC. Distribution of SUV-values of the primary tumors neither differed in early stage (10.0 ± 3.7 – HPVneg. vs. 8.2 ± 4.3 – HPVpos.; p=0.265) nor in late stage of the examination (11.5 ± 4.7 – HPVneg. vs. 10.0 ± 5.0 – HPVpos.; p=0.303). Likewise, there was no significant difference in SUV-values of cervical nodes in early stage (5.9 ± 2.3 – HPVneg. vs. 8.1 ± 4.8 – HPVpos.; p=0.516) or in late stage (7.6 ± 3.3 – HPVneg. vs. 9.9 ± 6.4 – HPVpos.; p=0.897).

Conclusion: Currently, there is no indication that FDG tracer-uptake differs between HPV-positive and HPV-negative OSCC. However, experimental research has shown that the HPV-E7 oncoprotein induces a high glucose metabolism within tumor cells. Therefore, the study results have to be proven with higher case numbers.